Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
Associated Therapies
-
Clinical Trials
Related News

Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Completed
Conditions
Social Phobia
Interventions
Drug: Paroxetine
First Posted Date
2011-06-20
Last Posted Date
2014-07-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
600
Registration Number
NCT01376271

Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

Completed
Conditions
Panic Disorder
Interventions
Drug: Paroxetine
First Posted Date
2011-06-20
Last Posted Date
2017-05-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
96
Registration Number
NCT01376128

Special Drug Use Investigation for PAXIL Tablet (Long-term)

Completed
Conditions
Mental Disorders
Interventions
Drug: Paroxetine
First Posted Date
2011-06-10
Last Posted Date
2017-06-08
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
339
Registration Number
NCT01371448

Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)

Completed
Conditions
Mental Disorders
Interventions
Drug: Paroxetine
First Posted Date
2011-06-10
Last Posted Date
2017-06-08
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
390
Registration Number
NCT01371461

Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

Completed
Conditions
Panic Disorder
Interventions
Drug: Paroxetine
First Posted Date
2011-06-10
Last Posted Date
2017-05-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1483
Registration Number
NCT01371474

Drug Use Investigation for PAXIL Tablet

Completed
Conditions
Mental Disorders
Interventions
Drug: Paroxetine
First Posted Date
2011-06-10
Last Posted Date
2017-06-08
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
3708
Registration Number
NCT01371435

Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder

First Posted Date
2011-05-16
Last Posted Date
2017-06-09
Lead Sponsor
Johns Hopkins University
Target Recruit Count
45
Registration Number
NCT01354314
Locations
🇺🇸

The Johns Hopkins Institute for Clinical and Translational Research, Adult Outpatient Clinical Research Unit, Baltimore, Maryland, United States

Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

First Posted Date
2010-05-25
Last Posted Date
2012-12-04
Lead Sponsor
Research Foundation for Mental Hygiene, Inc.
Target Recruit Count
37
Registration Number
NCT01130103
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Amitriptyline and Paroxetine Treatment of Major Depression

Phase 3
Completed
Conditions
Unipolar Depression
Interventions
Drug: amitriptyline
Drug: paroxetine
First Posted Date
2010-01-14
Last Posted Date
2024-01-31
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
127
Registration Number
NCT01049347
Locations
🇩🇪

Central Institute of Mental Health, Mannheim, Germany

Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation

Phase 3
Completed
Conditions
Premature Ejaculation
Interventions
Drug: placebo
Drug: paroxetine
First Posted Date
2009-12-02
Last Posted Date
2009-12-02
Lead Sponsor
MorePharma Corporation
Target Recruit Count
174
Registration Number
NCT01024491
Locations
🇲🇽

Asociacion Mexicana para la Salud Sexual, A.C., Mexico City, Mexico D.F., Mexico

🇲🇽

Centro Especializado en Urología y Andrología del Hospital Star Médica, Mexico City, Mexico D.F, Mexico

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy